Clinical features of liver injury induced by antitumor drugs: An analysis of 56 cases
10.3969/j.issn.1001-5256.2019.03.024
- VernacularTitle:56例抗肿瘤药物致肝损伤临床特点分析
- Author:
Huijuan ZHANG
1
;
Zuxuan SHI
;
Lanfang ZHAO
Author Information
1. Department of Medical Care, The First Affiliated Hospital of Hainan Medical College, Haikou 570102, China
- Publication Type:Research Article
- Keywords:
antineoplastic agents;
drug-induced liver injury
- From:
Journal of Clinical Hepatology
2019;35(3):574-578
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the clinical features of drug-induced liver injury (DILI) caused by antitumor drugs during the treatment of malignant tumors. MethodsA retrospective analysis was performed for the clinical data of 56 patients who were diagnosed with malignant tumors in Henan Provincial People′s Hospital from January 2015 to December 2016 and experienced DILI during the treatment with antitumor drugs, including sex, age, type of primary tumor, hepatotropic virus infection, liver function, type of chemotherapeutics, onset time of liver injury, application of liver-protecting drugs, and outcome of liver injury. ResultsAmong the 56 patients with DILI caused by antitumor drugs, 30 (53.6%) had hepatocellular injury, and 45 (80.4%) had mild liver injury. FOLFOX, GP/DP, and CHOP were the most common regimens for DILI, and of all 56 patients, 50 (89.3%) had DILI caused by multiple drugs. Platinum-based drugs, anti-microtubule agents, and alkylating agents were the common drugs causing DILI. Of all 56 patients, 35 (62.5%) developed DILI within 1-2 weeks after medication. ConclusionDILI caused by antitumor drugs mainly has a mild degree and hepatocellular injury type is the most common clinical type. Platinum-based antitumor drugs and related chemotherapeutic regimens are the most common drugs for DILI. A combination of multiple antitumor drugs is more likely to cause DILI, and patients with such DILI often have a good prognosis.
